尿路上皮癌分子亚型对新辅助化疗的反应不同
该回顾性队列研究对149例肌层浸润性膀胱癌患者进行肿瘤转录组分析和免疫组化分类,比较不同分子亚型在接受顺铂为基础的新辅助化疗后的病理完全缓解和生存。基因组不稳定型和尿路上皮样型肿瘤的病理完全缓解比例高于基底/鳞状亚型,基因组不稳定型和UroC肿瘤与更好的生存独立相关。
要点
- 基因组不稳定型和尿路上皮样型肿瘤的病理完全缓解比例分别为52%(16/31)和31%(17/54),基底/鳞状亚型为21%(5/24)。
- 与基底/鳞状亚型相比,基因组不稳定型肿瘤的生存风险比为0.29(95%CI 0.11-0.79),UroC型为0.37(95%CI 0.14-0.94)。
- SPP1基因表达对化疗反应具有亚型依赖性效应。
核心结论
- 腔样型(基因组不稳定型和尿路上皮样型)尿路上皮癌对顺铂为基础的新辅助化疗更敏感。
- 第二代亚型特异性生物标志物如SPP1可能有助于为肌层浸润性膀胱癌的新辅助化疗制定更精准的治疗策略。
研究设计与样本
- 回顾性队列研究,纳入149例患者,通过肿瘤转录组分析和免疫组化进行分子分型。
- 采用单纯根治性膀胱切除术治疗队列和公共数据集进行比较和外部验证。
主要发现
- 接受新辅助化疗和根治性膀胱切除术后,基因组不稳定型肿瘤的病理完全缓解比例为16/31(52%),尿路上皮样型为17/54(31%),基底/鳞状亚型为5/24(21%)。
- 调整临床分期后,与基底/鳞状肿瘤相比,基因组不稳定型肿瘤的生存风险比为0.29(95%CI 0.11-0.79),UroC肿瘤为0.37(95%CI 0.14-0.94)。
- SPP1基因表达对化疗反应显示出亚型依赖性效应。
临床怎么用
- 通过基因表达谱和分子分型可识别更可能从根治性膀胱切除术前化疗中获益的肌层浸润性膀胱癌患者。
- 分子亚型与其他反应标志物结合,可能有助于选择性实施此类化疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: For muscle-invasive bladder cancer (MIBC), no tissue biomarkers are available for clinical use to predict response to neoadjuvant chemotherapy. OBJECTIVE: To investigate how molecular subtypes impact pathological response and survival in patients receiving preoperative cisplatin-based chemotherapy. DESIGN, SETTING, AND PARTICIPANTS: Classification of a retrospective cohort of 149 patients was performed by tumor transcriptomic profiling and immunostaining. A cohort treated with radical cystectomy alone and public data sets were used for comparison and external validation. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Complete pathological response in the cystectomy specimen (ypT0N0) and survival were compared in predefined molecular subtypes. Differential gene expression and chemotherapy response were explored beyond molecular subtypes. RESULTS AND LIMITATIONS: Patients with genomically unstable (GU) and urothelial-like (Uro) tumors had higher proportions of complete pathological response (16/31 [52%] and 17/54 [31%]), versus five out of 24 (21%) with the basal/squamous (Ba/Sq) subtype following neoadjuvant chemotherapy and radical cystectomy. Molecular subtype was independently associated with improved survival for patients with GU tumors (hazard ratio [HR] 0.29, 95% confidence interval [CI]: 0.11-0.79) and UroC tumors (HR 0.37, 95% CI: 0.14-0.94) compared with Ba/Sq tumors, adjusting for clinical stage. In addition, expression of the gene coding for osteopontin (SPP1) showed a subtype-dependent effect on chemotherapy response. CONCLUSIONS: Urothelial cancer of the luminal-like (GU and Uro) subtypes is more responsive to cisplatin-based neoadjuvant chemotherapy. A second-generation of subtype-specific biomarkers, for example, SPP1, may be a way forward to develop a more precision-based treatment approach for neoadjuvant chemotherapy in MIBC. PATIENT SUMMARY: This study shows that tumor classification by gene expression profiling and molecular subtyping can identify patients who are more likely to benefit from chemotherapy before radical cystectomy for muscle-invasive bladder cancer. Together with other markers for response, molecular subtypes could have a role in selective administration of such chemotherapy.
引用
- Sjödahl G, Abrahamsson J, Holmsten K, et al. Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes. Eur Urol. 2021. PMID: 34782206. doi:10.1016/j.eururo.2021.10.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。